Key Insights

Highlights

Treatment Research

5 treatments under study, led by Nivolumab

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03799445Phase 2Terminated

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Showing all 1 trials

Research Network

Common Treatments

  • Nivolumab1
  • Intensitymodulated Radiation Therapy1
  • Qualityoflife Assessment1
  • Ipilimumab1
  • Questionnaire Administration1

Active Sponsors

  • National Cancer Institute (NCI)1
  • M.D. Anderson Cancer Center1

Top Investigators

Related Conditions

  • Stage Iii Oropharyngeal Squamous Cell Carcinoma Ajcc V71
  • Stage Iva Oropharyngeal Squamous Cell Carcinoma Ajcc V71
  • Soft Palate Squamous Cell Carcinoma1
  • Posterior Tongue Squamous Cell Carcinoma1
  • Pathologic Stage Ii Hpvmediated P16positive Oropharyngeal Carcinoma Ajcc V81

Activity Timeline